NCT01191944 - Pramipexole Extended Release Versus Pramipexole Immediate Release for 18 Weeks in Chinese Parkinson's Disease (PD) Patients | Biotech Hunter

Enrollment

475

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions

Parkinson Disease

Interventions

DRUG

pramipexole immediate release tablet

0.375mg-4.5mg(daily dose), three times a day

DRUG

pramipexole extended release tablet

0.375mg-4.5mg, once a day

Trial Locations (20)

248.671.86004 Boehringer Ingelheim Investigational Site, Beijing

248.671.86006 Boehringer Ingelheim Investigational Site, Beijing

248.671.86007 Boehringer Ingelheim Investigational Site, Beijing

248.671.86020 Boehringer Ingelheim Investigational Site, Beijing

248.671.86012 Boehringer Ingelheim Investigational Site, Chengdu

248.671.86013 Boehringer Ingelheim Investigational Site, Chongqing

248.671.86014 Boehringer Ingelheim Investigational Site, Chongqing

248.671.86008 Boehringer Ingelheim Investigational Site, Guangzhou

248.671.86009 Boehringer Ingelheim Investigational Site, Guangzhou

248.671.86017 Boehringer Ingelheim Investigational Site, Hangzhou

248.671.86018 Boehringer Ingelheim Investigational Site, Hangzhou

248.671.86005 Boehringer Ingelheim Investigational Site, Jinan

248.671.86002 Boehringer Ingelheim Investigational Site, Nanjing

248.671.86001 Boehringer Ingelheim Investigational Site, Shanghai

248.671.86003 Boehringer Ingelheim Investigational Site, Shanghai

248.671.86010 Boehringer Ingelheim Investigational Site, Shanghai

248.671.86011 Boehringer Ingelheim Investigational Site, Shenyang

248.671.86019 Boehringer Ingelheim Investigational Site, Suzhou

248.671.86015 Boehringer Ingelheim Investigational Site, Wuhan

248.671.86016 Boehringer Ingelheim Investigational Site, Wuhan